Here are the S-1 registration statements from Acurx Pharmaceuticals, Inc. (ACXP) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow ACXP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACXP filings page.
Acurx Pharmaceuticals, Inc. (ACXP) filed a Form S-1 to register 1,500,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC under an existing equity purchase agreement. These shares may be issued to Lincoln Park at Acurx’s discretion over a 24‑month term.
Acurx is a late-stage biopharmaceutical company developing Gram‑positive–targeted antibiotics, including candidates for Clostridioides difficile and other priority pathogens. The company has already sold $9.2 million of stock to Lincoln Park and may sell up to an additional $2.8 million, with proceeds intended for working capital, research and development, and general corporate purposes. Existing holders face potential dilution, and Lincoln Park is deemed an underwriter for these resale shares.
Acurx Pharmaceuticals, Inc. is registering 1,300,000 shares of common stock for resale by Lincoln Park Capital under an existing equity purchase agreement. These shares relate to an up to $12.0 million equity line, of which $7.3 million has already been drawn through sales of 1,835,000 shares.
Acurx will not receive proceeds from Lincoln Park’s resales, but may receive up to an additional $4.7 million from future share sales to Lincoln Park at its discretion. As of April 20, 2026, 4,278,492 shares were outstanding; if all 1,300,000 shares were issued, they would represent about 23% of outstanding stock. The prospectus highlights dilution and stock price pressure risks, alongside recent financing of approximately $2.5 million in an April 2026 registered direct offering and progress on its ibezapolstat program for recurrent C. difficile infection.
Acurx Pharmaceuticals, Inc. is filing an S-1 to register the resale of up to 1,650,170 shares of common stock issuable upon exercise of Series H warrants with a $2.78 per share exercise price. Only selling stockholders will receive resale proceeds; Acurx would receive up to about $4.6 million if all warrants are exercised for cash. These Series H warrants were issued in an April 2026 private placement tied to a concurrent $2.5 million registered direct offering. Acurx is a late-stage biopharmaceutical company developing Gram-positive targeted antibiotics and its stock trades on Nasdaq under the symbol ACXP.
Acurx Pharmaceuticals, Inc. is registering 750,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC under an existing equity purchase agreement. These shares are "Purchase Shares" that have been or may be issued to Lincoln Park under a $12.0 million commitment.
The company is not selling any shares in this prospectus and will not receive proceeds from Lincoln Park’s resales. However, Acurx may still receive up to $7.6 million in gross proceeds from future direct sales of common stock to Lincoln Park under the Purchase Agreement, separate from this resale.
As of January 30, 2026, Acurx had 2,546,717 common shares outstanding. If all 750,000 registered shares were issued, they would represent about 23% of total shares and about 24% of shares held by non-affiliates, increasing dilution for existing stockholders.